HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs.
https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform
Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.
German Federal Joint Committee (G-BA) says concizumab added benefit is not proven in haemophilia A
On 19 March 2026, the German Federal Joint Committee (G-BA) concluded that concizumab added benefit is not proven for routine prophylaxis of bleeding in people aged 12 years and older with severe haemophilia A and no factor VIII inhibitors. The core issue was evidence architecture, not a failed positive trial: the submitted package did not provide a relevant comparison against factor VIII prophylaxis or emicizumab, and no accepted indirect treatment comparison supported the claim.
Heutiger Posteingang 📬
Damit habe ich dann alle für mich relevanten NMA-Alben im Regal, nämlich von "Vengeance" (1984) bis "The Love of Hopeless Causes" (1993) 🙌
#newmodelarmy #nma #Alternative #music #independent #rock #folk #punk
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty.
https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
National Institute for Health and Care Excellence (NICE) clears fezolinetant when hormone replacement therapy is unsuitable
On 31 March 2026, the National Institute for Health and Care Excellence (NICE) published final guidance TA1143 recommending fezolinetant for moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy is unsuitable.
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier.
https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
When two network meta-analyses disagree: a playbook for similarity, consistency, and ranking discipline
A new commentary in the Journal of the European Academy of Dermatology and Venereology uses two recent hidradenitis suppurativa network meta-analyses as a warning against overinterpreting treatment rankings. For HTA, market access, and evidence teams, the operational lesson is clear: lock the decision question first, document similarity and inconsistency checks explicitly, and show how network design choices change the answer before a ranking enters a dossier.
HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook
France's Haute Autorité de Santé (HAS) publishes explicit validity conditions for indirect treatment comparison (ITC) evidence that diverge from the binary RCT-only stance historically associated with German AMNOG. Understanding these conditions — and how they intersect with IQWiG and NICE methodology — is one of the highest-leverage planning activities a global evidence team can perform. This playbook maps the HAS acceptability framework for network meta-analysis (NMA) evidence, compares it…
Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook
France and Germany impose distinct but reconcilable methodological requirements on indirect treatment comparison evidence. This playbook maps the divergences between HAS and IQWiG and provides an actionable architecture for building a single NMA and MAIC evidence package that satisfies both national agencies — reducing submission rework and eliminating cross-dossier inconsistency risk.
MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline
MHRA updates published between 12 and 18 March 2026 indicate a tighter operational cadence for patient information and medical device regulatory advice. This playbook translates those signals into concrete evidence-governance actions for HTA and market access teams.
EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority
EMA Management Board updates on 13 March 2026 position electronic product information and implementation governance as immediate evidence-operations triggers. This playbook shows how decision teams can operationalise change detection, ITC assumption control, and auditable rerun logic.
NMA outputs are now shaping HTA timelines before submission—not after. If your evidence plan starts late, your access strategy starts behind.
https://www.mattheneus.com/editorial/hta-value-nma-projections-evidence #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
How NMA Projections Reshape HTA Decision Timelines
Since the EU Health Technology Assessment Regulation (EU) 2021/2282 entered full application on 12 January 2025, network meta-analysis (NMA) outputs are being requested earlier in reimbursement workflows — including during joint scientific consultations before submission. This article examines what the shift means for evidence timing and how decision teams must adapt.
AbangeLabs
ᴺⁱˡᶻ 🍸